Literature DB >> 20662606

Cryopreservation of mononuclear cells before extracorporeal photochemotherapy does not impair their anti-proliferative capabilities.

Etienne Merlin1, Dalil Hannani, Richard Veyrat-Masson, Jacques Chassagne, Fraçoise Gabert, Marc Berger, François Deméocq, Joël Plumas, Justyna Kanold.   

Abstract

BACKGROUND AIMS: The clinical benefits of extracorporeal photochemotherapy (ECP) are well recognized, but its clinical use is limited by logistical difficulties, especially because of the need to perform repeated aphereses. The cryopreservation of mononuclear cells could allow maintenance of the ECP schedule while reducing the number of aphereses. The aim of this work was to assess whether previous cryopreservation impairs the immunomodulatory function of ECP-treated peripheral blood mononuclear cells (PBMC).
METHODS: Fresh or previously cryopreserved PBMC were exposed to ECP and added on day 0 into a mixed leukocyte reaction. Proliferation of alloreactive lymphocytes was measured by carboxyfluorescein succinimidyl ester (CFSE) dye dilution. Apoptosis was quantified by annexin-7AAD staining.
RESULTS: ECP-induced apoptosis was slightly increased in cryopreserved cells but the kinetics of apoptosis were similar to fresh cells. Lymphocytes stimulated in the presence of ECP-treated PBMC displayed a significant decrease in proliferation. The suppression was enforced when ECP-treated cells had been activated previously by allogeneic stimulation. Cryopreservation before ECP exposure did not impact apoptosis triggering or anti-proliferative properties of ECP-treated cells.
CONCLUSIONS: Cryopreservation before ECP does not impair the immunomodulatory effects of treated cells. These data warrant investigation of the clinical use of cryopreserved PBMC for ECP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662606     DOI: 10.3109/14653249.2010.501787

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  4 in total

1.  Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis.

Authors:  C Pochon; L Reppel; P Halle; A Zang; L Clément; D Michel; A Perrot; G Roth-Guépin; M Detrait; J Kanold; N Rouel; B Donzé; V Décot; S Mathieu-Nafissi; E Merlin; D Bensoussan
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

2.  Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry.

Authors:  Bo Li; Chunmei Yang; Gui Jia; Yansheng Liu; Na Wang; Fangfang Yang; Rui Su; Yulong Shang; Ying Han
Journal:  BMC Immunol       Date:  2022-06-07       Impact factor: 3.594

3.  Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models.

Authors:  Jennifer Schneiderman; Longhui Qiu; Xin Yi Yeap; Xin Kang; Feibo Zheng; Junsheng Ye; Yan Xie; Jiao-Jing Wang; Yuvaraj Sambandam; James Mathew; Lin Li; Joseph Leventhal; Richard L Edelson; Zheng Jenny Zhang
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

4.  European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Authors:  R Knobler; P Arenberger; A Arun; C Assaf; M Bagot; G Berlin; A Bohbot; P Calzavara-Pinton; F Child; A Cho; L E French; A R Gennery; R Gniadecki; H P M Gollnick; E Guenova; P Jaksch; C Jantschitsch; C Klemke; J Ludvigsson; E Papadavid; J Scarisbrick; T Schwarz; R Stadler; P Wolf; J Zic; C Zouboulis; A Zuckermann; H Greinix
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-06       Impact factor: 6.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.